759 related articles for article (PubMed ID: 30328672)
1. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
2. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
3. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
[TBL] [Abstract][Full Text] [Related]
4. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
5. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
6. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
7. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
8. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
Hammer M; Bagley S; Aggarwal C; Bauml J; Nachiappan AC; Simone CB; Langer C; Katz SI
Curr Probl Diagn Radiol; 2019; 48(2):142-147. PubMed ID: 29573843
[TBL] [Abstract][Full Text] [Related]
9. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
[TBL] [Abstract][Full Text] [Related]
10. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
[TBL] [Abstract][Full Text] [Related]
11. Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.
Mayoral M; Castañer E; Gallardo X; Andreu M; Dalmau E; Garcia Y
Radiologia (Engl Ed); 2019; 61(6):498-505. PubMed ID: 31300214
[TBL] [Abstract][Full Text] [Related]
12. Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer.
Ando C; Ichihara E; Kano H; Iwamoto Y; Hirabae A; Nakasuka T; Maeda Y; Kiura K
In Vivo; 2019; 33(6):2113-2115. PubMed ID: 31662545
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
14. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.
Juergens RA; Mariano C; Jolivet J; Finn N; Rothenstein J; Reaume MN; Faghih A; Labbé C; Owen S; Shepherd FA; Villeneuve J; Romeyer F; Pettersson F; Butts C
Curr Oncol; 2018 Dec; 25(6):384-392. PubMed ID: 30607113
[TBL] [Abstract][Full Text] [Related]
15. Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
Yano Y; Kurebe H; Edahiro R; Hosono Y; Nakatsubo S; Nishida K; Sawa N; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
PLoS One; 2018; 13(8):e0203070. PubMed ID: 30153300
[TBL] [Abstract][Full Text] [Related]
16. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Mouri A; Kaira K; Yamaguchi O; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):873-880. PubMed ID: 31444618
[TBL] [Abstract][Full Text] [Related]
17. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
[TBL] [Abstract][Full Text] [Related]
18. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
